BBS5 Antibodies

Santa Cruz Biotechnology features a diverse variety of BBS5 monoclonal antibodies for investigating Bardet-Biedl Syndrome 5 (BBS5) in cellular processes. BBS5 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). BBS5 functions as a key component of the BBSome complex, playing an essential role in cilia function and regulating signaling pathways involved in development and cellular communication. Mutations in BBS5 are linked to Bardet-Biedl Syndrome, which manifests through symptoms including obesity, retinal degeneration, and renal abnormalities. Research focusing on BBS5 continues to reveal new insights about its role in cellular processes and disease mechanisms. Understanding BBS5 function is crucial for developing new therapeutic approaches for Bardet-Biedl Syndrome and related disorders. Investigating BBS5 helps researchers better comprehend ciliary biology and its impact on human health. Current studies are uncovering novel aspects of BBS5's involvement in cellular signaling and development. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of BBS5 and its implications in human health and disease.